Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genscript Biotech's share price for the quarter that ended in Dec. 2023 was HK$19.86. Genscript Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 2,121 Mil. Therefore, Genscript Biotech's market cap for the quarter that ended in Dec. 2023 was HK$42,116 Mil.
Genscript Biotech's quarterly market cap
declined
from Dec. 2022 (HK$52,464 Mil) to Jun. 2023 (HK$37,242 Mil) but then
increased
from Jun. 2023 (HK$37,242 Mil) to Dec. 2023 (HK$42,116 Mil).
Genscript Biotech's annual market cap
declined
from Dec. 2021 (HK$72,301 Mil) to Dec. 2022 (HK$52,464 Mil) and
declined
from Dec. 2022 (HK$52,464 Mil) to Dec. 2023 (HK$42,116 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genscript Biotech's Enterprise Value for Today is HK$8,179 Mil.
Genscript Biotech Market Cap Historical Data
The historical data trend for Genscript Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genscript Biotech's Market Cap
For the Biotechnology subindustry, Genscript Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Market Cap falls into.
Genscript Biotech Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genscript Biotech's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (HKSE:01548) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genscript Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Genscript Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Genscript Biotech (HKSE:01548) Business Description
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01548 has been successfully added to your 